Does the New Peptide Policy Mean These Treatments Are Safe? What Patients Should Know
Peptides have been getting a lot of attention lately, with claims that they can help with everything from weight loss and muscle recovery to inflammation and anti-aging. Now, a new federal policy has brought some of these substances further into the spotlight.
On October 28, 2026, the U.S. Department of Health and Human Services (HHS) announced a draft interim enforcement discretion policy that addresses the compounding of six peptides under specific conditions.
But what does this change actually mean for patients? Does it mean these peptides are now FDA-approved or that they've been proven safe and effective? Not necessarily. Christine Bonarrigo, PharmD, BCPP, weight management clinical pharmacist at Tufts Medicine Primary Care, explains what the policy means and what patients should consider before trying peptide therapy.
What exactly did HHS announce?
The October 28 announcement covers six peptides: BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax. The draft policy would allow certain qualifying 503A compounding pharmacies, federal facilities and licensed physicians to compound these substances under specified conditions while the FDA continues to evaluate their status.
Compounding is the process of preparing a medication to meet an individual patient's needs. For example, a pharmacist may customize a medication's dosage or formulation when an FDA-approved option isn't available in a form that meets a patient's needs.
It's important to understand what this policy means. An enforcement discretion policy outlines circumstances in which the government generally does not intend to take enforcement action. It is not the same as formal FDA approval, and it does not mean these peptides have been proven safe or effective. The policy is also limited to qualifying compounders that meet the applicable requirements, not all compounding pharmacies.
Does this mean these peptides are FDA-approved?
No. FDA-approved medications go through a rigorous review process to evaluate their safety, effectiveness and manufacturing quality for specific uses. Compounded medications are different. They are not FDA-approved, and the FDA does not review them in the same way before they are dispensed.
The distinction is important because a change in how a medication may be compounded does not establish that it works or that its benefits outweigh its risks.
Does the new policy change what we know about peptide safety?
No. While the policy addresses how certain peptides may be compounded, it doesn't change what researchers know about their safety or effectiveness.
Many of these substances have limited research in people. There are still questions about appropriate dosing, potential side effects, interactions with other medications and long-term safety.
"Even if a product is pure and free of contaminants, that doesn't mean we fully understand how it will affect the body," says Bonarrigo.
Product quality and clinical safety are two different things. Testing may help identify issues with purity or contamination, but it doesn't establish that a substance is safe or that it will provide the benefits being advertised.
How are these peptides different from FDA-approved medications?
Not all peptides are the same. Some have become FDA-approved medications supported by extensive clinical research. For example, semaglutide and tirzepatide are peptide-based medications approved for specific medical conditions, including certain uses in treating obesity and type 2 diabetes.
Other peptides are still investigational, meaning researchers are studying whether they work and whether they're safe for people. A peptide's natural presence in the body or promising early research doesn't necessarily mean taking it as a medication will be safe or effective.
It's also important to remember that compounded versions of FDA-approved medications are not automatically FDA-approved simply because they contain the same active ingredient.
What if you're already taking peptides?
If you're already taking peptides, it's important to tell your doctor. Your healthcare team needs to know what you're taking to help identify potential side effects, interactions with other medications and other risks. With unapproved peptides, there may be limited safety information, and the actual contents or concentration of a product may not always match what's listed on the label.
Your doctor needs the full picture to help keep you safe. Being open about what you're taking helps them make informed decisions about your care.
Christine Bonarrigo, PharmD, BCPP, weight management clinical pharmacist at Tufts Medicine Primary Care
You don't need to feel uncomfortable bringing it up. Your healthcare team is there to help you understand the risks, not to judge you. Bring any product information you have, including its name, source, dosage and how you're taking it.
What should you consider before trying peptide therapy?
If you're considering peptide therapy, start by talking with your doctor. They can help you understand what is known about a particular substance, what remains uncertain and whether there are better-studied treatment options for your needs.
Bonarrigo recommends asking questions such as:
- Is there good human research showing that this peptide works for my condition?
- What are the known risks, and what do we still not know?
- Is there an FDA-approved treatment with stronger evidence?
- Where is the product coming from, and what quality testing is performed?
It's also important to be cautious about products marketed online, particularly those labeled for research use. These products are not intended for human use, and their quality, contents and safety may be uncertain. Avoid purchasing peptides from unverified sources or attempting to prepare or inject them yourself.
If you're considering a compounded medication, ask about the pharmacy and whether the treatment is appropriate for your needs. Learn more about what you should know before trying peptides.
The bottom line
The new HHS policy addresses the enforcement approach to compounding certain peptides under specified conditions. It does not mean these substances have been FDA-approved or that researchers have answered all the questions about their safety and effectiveness.
Some peptides have become well-established medications, while others still have limited evidence in people. As interest in peptide therapy continues to grow, it's important to look beyond the claims and understand what the research actually shows.
If you're considering peptide therapy or already taking these products, talk with your doctor. Together, you can review the available evidence, discuss potential risks and benefits and determine whether there are better-studied treatment options for your health needs.
Your primary care clinician is your partner in staying healthy. Whether you're considering a new treatment, managing a chronic condition or simply have questions about your health, they can help you make informed decisions about your care.
Looking for a primary care doctor?